Takeda Pharma logs surprise profit, updates on COVID-19 therapy
Share:
TOKYO/NEW YORK (Reuters) - Takeda Pharmaceutical Co booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede.Takeda also said it could start clinical trials in July for its plasma-derived therapy for COVID-19, initially called TAK-888, according to plasma division President Julie Kim.Japan's largest drugmaker estimated 355 billion yen (2.70 billion pounds)in operating profit..